Carregant...
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/208421
Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
We investigated >= grade 3 (CTC-AE) organ toxicities for commercial CD19 chimeric antigen receptor T cell (CAR-T cell) products in 492 patients (Axi-Cel; n = 315; Tisa-Cel; n = 177) with Large B-cell Lymphoma in the European Society for Blood and Marrow Transplantation (EBMT) CAR-T registry. The incidence of >= grade 3 organ toxicities during the first 100 days after CAR-T was low and the most frequent were: renal (3.0%), cardiac (2.3%), gastro-intestinal (2.3%) and hepatic (1.8%). The majority occurred within three weeks after CAR-T cell therapy. Overall survival was 83.1% [79.8-86.5; 95% CI] at 3 months and 53.5% [49-58.4; 95% CI] at one year after CAR-T. The most frequent cause of death was tumour progression (85.1%). Non-relapse mortality was 3.1% [2.3-4.1; 95% CI] at 3 months and 5.2% [4.1-6.5; 95% CI] at one year after CAR-T. The most frequent causes of non-relapse mortality were cell-therapy-related toxicities including organ toxicities (6.4% of total deaths) and infections (4.4% of total deaths). Our data demonstrates good safety in the European real-world setting.
Matèries
Matèries (anglès)
Citació
Citació
PENACK, Olaf, PECZYNSKI, Christophe, KOENECKE, Christian, POLGE, Emmanuelle, SANDERSON, Robin, YAKOUB AGHA, Ibrahim, FEGUEUX, Nathalie, DASKALAKIS, Michael, COLLIN, Matthew, DREGER, Peter, KRÖGER, Nicolaus, SCHANZ, Urs, BLOOR, Adrian, GANSER, Arnold, BESLEY, Caroline, WULF, Gerald g., NOVAK, Urban, MOISEEV, Ivan, SCHOEMANS, Hélène, BASAK, Grzegorz w., CHABANNON, Christian, SUREDA, Anna, GLASS, Bertram, PERIC, Zinaida. Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party. _Frontiers in Immunology_. 2023. Vol. 14. [consulta: 22 de gener de 2026]. ISSN: 1664-3224. [Disponible a: https://hdl.handle.net/2445/208421]